Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA
- Categories:News
- Author:
- Origin:
- Time of issue:2024-02-01
- Views:0
(Summary description)At the beginning of 2024, PudaoPharma, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had drug license of Ebastine oral solution from NMPA. PudaoPharma is the first enterprise to obtain this dosage form license of Ebastine in China.
Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA
(Summary description)At the beginning of 2024, PudaoPharma, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had drug license of Ebastine oral solution from NMPA. PudaoPharma is the first enterprise to obtain this dosage form license of Ebastine in China.
- Categories:News
- Author:
- Origin:
- Time of issue:2024-02-01
- Views:0
At the beginning of 2024, PudaoPharma, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had drug license of Ebastine oral solution from NMPA. PudaoPharma is the first enterprise to obtain this dosage form license of Ebastine in China.
Jiudian Pharmaceutical also the MAH of Ebastine tablets. There are four MAH of it in China at present.
The annual marketing turnover of tablets is 550 million RMB in public hospital in 2022.
Scan the QR code to read on your phone